서방형 첨가제 시장 - 예측(2026-2031년)

Sustained Release Excipients Market, sustaining a 7.55% CAGR, is anticipated to reach USD 2.536 billion in 2031 from USD 1.639 billion in 2025.

The sustained release excipients market is a specialized and critical segment within the broader pharmaceutical excipients industry, focused on the functional ingredients that enable controlled and prolonged drug release from a dosage form. These excipients are engineered to modulate the dissolution, diffusion, or erosion of the active pharmaceutical ingredient (API), thereby extending its therapeutic effect, reducing dosing frequency, and improving patient compliance. Primarily utilized in oral solid dosage forms like tablets and capsules, these functional materials are fundamental to developing advanced drug delivery systems that meet evolving clinical and patient-centric needs.

A primary driver of market growth is the increasing demand for patient-friendly dosage forms tailored to specific populations, particularly the elderly and pediatric patients. For these groups, simplified dosing regimens-achieved through once-daily or less-frequent administration-are crucial for improving adherence and therapeutic outcomes. Sustained release formulations address this need directly, creating a strong incentive for pharmaceutical developers to incorporate specialized release-modifying excipients into new and lifecycle-managed products. This demographic trend underpins a sustained demand for innovative excipient solutions.

The market is further propelled by the expanding use and continuous advancement of pharmaceutical polymers, which constitute the core technology for most sustained release mechanisms. Polymers such as hypromellose (HPMC), ethyl cellulose, polyvinyl acetate, and various polymethacrylates are engineered to provide precise control over drug release kinetics. Their evolution from simple binding agents to sophisticated, multifunctional excipients capable of enabling targeted release profiles (e.g., pH-dependent, time-controlled) is a key innovation driver. The performance, consistency, and regulatory acceptance of these polymers make them indispensable for formulators developing complex generic and novel sustained release products.

The dominance of oral drug delivery as the preferred administration route significantly influences the market. Oral dosage forms offer unparalleled advantages in terms of patient acceptance, manufacturing scalability, and cost-effectiveness. Within this segment, the development of sustained release tablets and capsules represents a major focus area for improving drug performance. The relative regulatory familiarity with oral modified-release technologies, compared to more novel delivery routes, facilitates development and approval, encouraging pharmaceutical companies to leverage sustained release excipients to enhance product value and differentiation.

A notable macro-level driver is the global challenge of antimicrobial resistance (AMR). Inappropriate use of immediate-release antibiotics, often due to complex dosing schedules leading to patient non-adherence, is a recognized contributor to resistance. Sustained release formulations that maintain effective drug concentrations over longer periods with fewer doses can support more complete treatment courses and improved adherence, potentially mitigating one factor in resistance development. This public health imperative encourages exploration of controlled-release strategies for anti-infectives, creating a specific, though niche, growth avenue for relevant excipient technologies.

The market also benefits from the broader trend of pharmaceutical companies utilizing drug delivery technologies, including sustained release, to differentiate products and extend commercial lifecycles, especially in the face of patent expirations. Reformulating an existing API into a controlled-release version can offer clinical benefits, improve market competitiveness, and provide a pathway for lifecycle management, thereby driving demand for the excipients that enable such innovations.

Geographically, North America remains a mature and dominant market. This leadership is supported by a concentration of multinational pharmaceutical companies with extensive R&D capabilities, a robust generic drug industry active in developing complex generics (including modified-release products), and a well-defined regulatory framework from the U.S. Food and Drug Administration (FDA). The region's focus on advanced drug delivery and patient-centric dosage forms sustains high demand for high-performance excipients.

Concurrently, the Asia-Pacific region is identified as a high-growth market with significant potential. This is driven by the rapid expansion of regional pharmaceutical manufacturing capabilities, increasing investment in healthcare infrastructure, a growing burden of chronic diseases requiring long-term medication, and the rising localization of excipient production by global suppliers to serve this expanding market. The region presents a substantial opportunity for growth as pharmaceutical standards and innovation continue to advance.

The competitive landscape features major specialty chemical and excipient manufacturers that compete on the basis of product portfolio breadth, technical expertise, consistency, regulatory support, and the ability to provide robust scientific data to formulators. Strategic activities, including mergers, acquisitions, and partnerships, are common as companies seek to expand their technology platforms, gain access to novel polymer chemistries, and strengthen their global commercial footprint.

In conclusion, the sustained release excipients market is integral to the development of modern, patient-centered pharmaceuticals. Its growth is underpinned by enduring needs for improved medication adherence, the sophistication of polymer science, and the strategic use of drug delivery to enhance therapeutic value. Future development will be shaped by innovations in multifunctional and "smart" excipients that respond to physiological triggers, the increasing demand for complex generic products, and the need for excipients that support the development of sustained release formulations for challenging APIs, including poorly soluble drugs. Success in this market requires a deep understanding of formulation science, close collaboration with pharmaceutical developers, and a commitment to quality and innovation in functional material design.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Sustained Released Excipients Market Segmentation

• By Type
• Polymers
• Lipids
• Micrspheres
• By Product Type
• Tablets & Capsules
• Patches
• Implants
• Others
• By Route of Administration
• Oral
• Injectables
• Transdermal
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SUSTAINED RELEASED EXCIPIENTS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Polymers
• 5.3. Lipids
• 5.4. Micrspheres

6. SUSTAINED RELEASED EXCIPIENTS MARKET BY PRODUCT TYPE

• 6.1. Introduction
• 6.2. Tablets & Capsules
• 6.3. Patches
• 6.4. Implants
• 6.5. Others

7. SUSTAINED RELEASED EXCIPIENTS MARKET BY ROUTE OF ADMINISTRATION

• 7.1. Introduction
• 7.2. Oral
• 7.3. Injectables
• 7.4. Transdermal
• 7.5. Others

8. SUSTAINED RELEASED EXCIPIENTS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. BASF SE
• 10.2. International Flavors & Fragrances, Inc.
• 10.3. Ashland
• 10.4. Evonik Industries
• 10.5. Croda International Plc
• 10.6. Gattefosse
• 10.7. Merck KGaA
• 10.8. MEGGLE GmbH & Co. KG
• 10.9. Roquette Freres
• 10.10. CD Formulation

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations